Excited to share the second paper from our lab!
We found that intercellular crosstalk in TME amplifies IL-1β signaling to drive chemoresistance in metastatic ovarian cancer.
Should IL-1β pathway antagonists be considered as part of neoadjuvant therapy?
https://t.co/sQuIu36Cjp
Excited to share our new paper: 'LASER couples damage sensing to ESCRT assembly for lysosome repair.' Congrats to dream team @clairegoul and @aakritijain24 for uncovering a new lysosome repair pathway and its connection to neurodegeneration. https://t.co/ZdGtlU0wke
@addictedtoigno1 IMO if an entire claim of senescence in a paper is based solely on p16 expression, the paper has a bigger (conceptual) red flag than the antibody itself.
Published in Nature, new research from the Icahn School of Medicine at Mount Sinai reveals that people at the extreme high or low ends of traits like cholesterol, blood glucose, height, and age at menopause may have a different genetic architecture than previously understood.
Led by Paul O’Reilly, PhD, the study found that while many health-related traits are considered “polygenic” — shaped by thousands of small genetic changes — individuals with especially extreme trait values may instead carry rare genetic variants with much larger biological effects.
Analyzing 74 quantitative traits across major datasets including the UK Biobank and the All of Us Research Program, the researchers developed new statistical approaches to identify how rare variants may contribute to disease-related traits linked to diabetes, heart disease, stroke, and more.
The findings offer a new framework for understanding human disease risk and could help researchers uncover biological pathways that are especially important in disease development — ultimately advancing more personalized prevention and treatment strategies.
Read the full study here: https://t.co/Crcm6Pahq1
It's time to rewrite reviews-aKG doesn't just regulate demethylation. Work from my lab and @mzspectrum demonstrates a new role for aKG in promoting histone acetylation and DNA repair through regulating carnitine synthesis. Congrats @ApoorvaUboveja!
https://t.co/o4ekqG9E4Y
@jaguimera Jo crec que hem d’acceptar que utilitzaràn IA, perquè és una eina més. El repte es adaptar l’avaluació. La IA generalment és poc concreta, així que hem de fer preguntes concretes que ens permeten vore si realment saben defensar, explicar i raonar les idees que presenten.
I moved to the U.S 10 years ago dreaming about helping develop a novel model of #Alzheimer, closer to humans. Happy to share that our last study at the journal of the @alzassociation, was within the top 10% most-viewed in 2024. The model now is being used to test therapies 🤓🧠
Science publishing giant Elsevier has joined the dozens of firms and individuals suing artificial intelligence companies over their alleged use of copyrighted works in training AI models
https://t.co/0Ni7HQzrk2
🔵🔴 Una de les imatges de la rua del Barça que emet TV3
📺 Marc Casadó, Gerard Martin i Pau Cubarsí es cruspeixen un fuet a queixalades a l'autobus. Li ofereixen a Cancelo, que ho mira sense entendre gaire que fan
The ERC just adjusted its resubmission rules after backlash.
But this episode reveals something deeper.
There are two strategic mistakes in how Europe is handling frontier research. 🧵👇🏼
5/ Restricting resubmissions may reduce pressure on panels.
But it does NOT solve the real issue: structural underinvestment.
The ERC is a victim of its own success:
It attracts the best ideas globally…
but lacks the resources to support them.